Short-term (2-week) effects of discontinuing milnacipran in patients with fibromyalgia

References

• Wolfe F, Anderson J, Harkness D, et al. Health status and disease severity in fibromyalgia: results of a six-center longitudinal study. Arthritis Rheum 1997;40:1571-9
   PubMed Web of Science ®Google Scholar
• Wolfe F, Ross K, Anderson J, et al. The prevalence and characteristics of fibromyalgia in the general population. Arthritis Rheum 1995;38:19-28
   PubMed Web of Science ®Google Scholar
• Wolfe F, Smythe HA, Yunus MB, et al. The American College of Rheumatology 1990 criteria for the classification of fibromyalgia. Report of the Multicenter Criteria Committee. Arthritis Rheum 1990;33:160-72
   PubMed Web of Science ®Google Scholar
• Mease PJ, Clauw DJ, Arnold LM, et al. Fibromyalgia syndrome. J Rheumatol 2005;32:2270-7
   PubMed Web of Science ®Google Scholar
• Mease P, Arnold LM, Choy EH, et al. Fibromyalgia syndrome module at OMERACT 9: domain construct. J Rheumatol 2009;36:2318-29
   PubMed Web of Science ®Google Scholar
• Mease PJ, Clauw DJ, Gendreau RM, et al. The efficacy and safety of milnacipran for treatment of fibromyalgia. A randomized, double-blind, placebo-controlled trial. J Rheumatol 2009;36:398-409 [published correction appears in J Rheumatol 2009;36:661]
   PubMed Web of Science ®Google Scholar
• Clauw DJ, Mease P, Palmer RH, et al. Milnacipran for the treatment of fibromyalgia in adults: a 15-week, multicenter, randomized, double-blind, placebo-controlled, multiple-dose clinical trial. Clin Ther 2008;30:1988-2004 [published correction appears in Clin Ther 2009;31:446]
   PubMed Web of Science ®Google Scholar
• Branco JC, Zachrisson O, Perrot S, et al. A European multicenter randomized double-blind placebo-controlled monotherapy clinical trial of milnacipran in treatment of fibromyalgia. J Rheumatol 2010;37:851-9
   PubMed Web of Science ®Google Scholar
• Arnold LM, Gendreau RM, Palmer RH, et al. Efficacy and safety of milnacipran 100 mg/day in patients with fibromyalgia: results of a randomized, double-blind, placebo-controlled trial. Arthritis Rheum 2010;62:2745-56
   PubMed Web of Science ®Google Scholar
• Burckhardt CS, Clark SR, Bennett RM. The fibromyalgia impact questionnaire: development and validation. J Rheumatol 1991;18:728-33
   PubMed Web of Science ®Google Scholar
• Cleeland CS, Ryan KM. Pain assessment: global use of the Brief Pain Inventory. Ann Acad Med Singapore 1994;23:129-38
   PubMedGoogle Scholar
• Smets EM, Garssen B, Bonke B, et al. The Multidimensional Fatigue Inventory (MFI) psychometric qualities of an instrument to assess fatigue. J Psychosom Res 1995;39:315-25
   PubMed Web of Science ®Google Scholar
• Ware JE Jr, Sherbourne CD. The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection. Med Care 1992;30:473-83
   PubMed Web of Science ®Google Scholar
• Seidenberg M, Haltiner A, Taylor MA, et al. Development and validation of a Multiple Ability Self-Report Questionnaire. J Clin Exp Neuropsychol 1994;16:93-104
   PubMed Web of Science ®Google Scholar
• Dworkin RH, Turk DC, Wyrwich KW, et al. Interpreting the clinical importance of treatment outcomes in chronic pain clinical trials: IMMPACT recommendations. J Pain 2008;9:105-21
   PubMed Web of Science ®Google Scholar
• Farrar JT, Young JP Jr, LaMoreaux L, et al. Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale. Pain 2001;94:149-58
   PubMed Web of Science ®Google Scholar
• Strand V, Singh JA. Improved health-related quality of life with effective disease-modifying antirheumatic drugs: evidence from randomized controlled trials. Am J Manag Care 2008;14:234-54
   PubMed Web of Science ®Google Scholar
• Dunkl PR, Taylor AG, McConnell GG, et al. Responsiveness of fibromyalgia clinical trial outcome measures. J Rheumatol 2000;27:2683-91
   PubMed Web of Science ®Google Scholar
• Cymbalta [package insert]. Indianapolis, IN, USA: Eli Lilly and Company, September 2011. Available at: www.cymbalta.com [Last accessed 19 January 2012]
   Google Scholar
• Savella [package insert]. St. Louis, MO, USA: Forest Laboratories, Inc., November 2011. Available at: www.savella.com [Last accessed 10 January 2012]
   Google Scholar
• Clauw DJ, Mease PJ, Ma Y, et al. Continuing efficacy of milnacipran demonstrated after long-term treatment of fibromyalgia [abstract]. Arthritis Rheum 2011;63:S365
   PubMed Web of Science ®Google Scholar
• Mease PJ, Clauw DJ, Ma Y, et al. Return of pain and functional impairment after discontinuation of milnacipran in patients with fibromyalgia [abstract]. Arthritis Rheum 2011;63:S742
   Google Scholar
• Montgomery SA. Tolerability of serotonin norepinephrine reuptake inhibitor antidepressants. CNS Spectr 2008;13:27-33
   PubMed Web of Science ®Google Scholar
• Forest Research Institute, Inc. Data on file
   Google Scholar